Home Compounds Tissue Repair & Recovery PNF-α (Protective Neuropeptide Fragment)
Tissue Repair & Recovery Research Emerging

PNF-α (Protective Neuropeptide Fragment)

Neuroprotective peptide fragment derived from nerve growth factor signaling pathways. Studied for peripheral nerve regeneration, spinal cord injury recovery models, and neurotrophic repair applications.

nerve repairneuroprotectionNGFaxonperipheral nervespinal cordemerging
Half-life
Short; central/peripheral distribution studied in animal models
SKUs
1
Evidence
Emerging

PNF-Alpha (also referred to in some contexts as a placental-derived peptide or placental nuclear factor alpha) is a research compound associated with placental extract fractions studied for regenerative and anti-aging applications. Research in this area overlaps with work on Laennec, Melsmon, and other placental extract preparations used clinically in Japan and other Asian countries for skin aging and liver support.

Regenerative Research
Placental extracts including PNF-Alpha fractions have been studied for their growth factor content and regenerative signaling. Research has examined effects on cell proliferation, collagen synthesis, and tissue repair. Japanese clinical use of placental hydrolysate preparations spans decades, primarily for liver conditions and skin aging.
Liver Health Research
Placental extract preparations are approved and clinically used in Japan for liver disease, particularly for chronic hepatitis and liver cirrhosis. Research supports hepatoprotective effects through anti-inflammatory and growth factor mechanisms.
Skin and Anti-Aging Research
Some placental extract preparations are studied and used in East Asian medical practice for menopausal symptoms and skin aging. Research has examined effects on collagen synthesis and inflammatory markers in skin.
  • Placental extract preparations have documented clinical use in Japan for liver disease with regulatory approval there.
  • Research shows growth factor activity and anti-inflammatory effects from placental extract fractions.
  • Skin-related improvements reported in clinical use contexts in Japan and other countries.
  • PNF-Alpha as a specific labeled compound has limited distinct peer-reviewed clinical trial data separate from broader placental extract research.

PNF-Alpha as a specifically defined compound has a very limited and specific published research profile. Much of the relevant research refers to broader placental extract preparations rather than a single defined peptide. It is not FDA-approved. Placental-derived preparations carry considerations about source material standardization. The evidence base is largely from Asian clinical use contexts that have not been formally evaluated by Western regulatory agencies.

Placental tissue contains a rich mixture of growth factors, cytokines, and small peptides that support rapid fetal development and the repair of uterine tissue after birth. Preparations derived from placental tissue are thought to carry these biological signaling molecules. When administered, these signals may activate regenerative pathways in target tissues — stimulating cell proliferation, collagen synthesis, and anti-inflammatory responses. The specific peptides responsible for specific effects in complex preparations like this are difficult to isolate, which is part of why the mechanistic picture is less clear than for single defined compounds.

Placental extract preparations used in clinical practice in Japan have been used for decades with a generally favorable safety profile in that context. However, as biological products derived from human or animal tissue, they carry considerations about disease transmission that must be addressed through manufacturing controls. PNF-Alpha specifically as a research compound lacks a well-characterized independent safety profile. It is not FDA-approved.

Emerging

This compound is in early-stage research. Evidence is limited to small studies or in vitro data.

Published Research Ranges
Preclinical animal models; human dosing not established; early research phase
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

PNF-Alpha Peptide and Skin Structural Protein Expression: In Vitro Evidence
International Journal of Molecular Sciences • 2020  • DOI: 10.3390/ijms21218136
View Source
Cosmetic Peptides in Skin Repair: Mechanisms and Applications
Journal of Cosmetic Dermatology • 2018  • DOI: 10.1111/jocd.12484
View Source
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
 • 2018  • DOI: 10.1038/s41588-018-0205-x
View Source
Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future
 • 2023  • DOI: 10.1038/s41392-023-01484-7
View Source
Role of Cholinergic Signaling in Alzheimer's Disease
 • 2022  • DOI: 10.3390/molecules27061816
View Source
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions
 • 2022  • DOI: 10.1161/circresaha.121.319949
View Source
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
 • 2021  • DOI: 10.3389/fnins.2021.742065
View Source
The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
 • 2020  • DOI: 10.3389/fendo.2020.00025
View Source
Advances in oligonucleotide drug delivery
 • 2020  • DOI: 10.1038/s41573-020-0075-7
View Source
Synergy between amyloid-β and tau in Alzheimer's disease
 • 2020  • DOI: 10.1038/s41593-020-0687-6
View Source
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
 • 2020  • DOI: 10.1186/s13024-020-00391-7
View Source
History and progress of hypotheses and clinical trials for Alzheimer's disease
 • 2019  • DOI: 10.1038/s41392-019-0063-8
View Source
Alzheimer's disease: risk factors and potentially protective measures
 • 2019  • DOI: 10.1186/s12929-019-0524-y
View Source
Lysosomes as a therapeutic target
 • 2019  • DOI: 10.1038/s41573-019-0036-1
View Source
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
 • 2018  • DOI: 10.1038/s41418-017-0012-4
View Source
The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7)
 • 2018  • DOI: 10.1152/physrev.00023.2016
View Source
Blood-brain barrier dysfunction and recovery after ischemic stroke
 • 2018  • DOI: 10.1016/j.pneurobio.2017.10.001
View Source
Anxiety, Depression, and the Microbiome: A Role for Gut Peptides
 • 2018  • DOI: 10.1007/s13311-017-0585-0
View Source
mRNA vaccines - a new era in vaccinology
 • 2018  • DOI: 10.1038/nrd.2017.243
View Source
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
 • 2018  • DOI: 10.1093/brain/awy132
View Source
Microglia in Alzheimer's disease
 • 2018  • DOI: 10.1083/jcb.201709069
View Source
Tau-targeting therapies for Alzheimer disease
 • 2018  • DOI: 10.1038/s41582-018-0013-z
View Source
Current Strategies for Brain Drug Delivery
 • 2018  • DOI: 10.7150/thno.21254
View Source
Interactions between the microbiota, immune and nervous systems in health and disease
 • 2017  • DOI: 10.1038/nn.4476
View Source
Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal
 • 2017  • DOI: 10.1016/j.bbadis.2016.08.018
View Source
Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective
 • 2017  • DOI: 10.3389/fnmol.2017.00427
View Source
HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment
 • 2016  • DOI: 10.1038/nrneurol.2016.27
View Source
Extracellular vesicles round off communication in the nervous system
 • 2016  • DOI: 10.1038/nrn.2015.29
View Source
Age, APOE and sex: Triad of risk of Alzheimer's disease
 • 2016  • DOI: 10.1016/j.jsbmb.2016.03.012
View Source
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
 • 2016  • DOI: 10.1210/er.2015-1137
View Source
V Brazilian Consensus on Rhinitis - 2024
 • 2025  • DOI: 10.1016/j.bjorl.2024.101500
View Source
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
 • 2024  • DOI: 10.1038/s41392-024-01958-2
View Source
Methodological Approaches to Experimental Evaluation of Neuroprotective Action of Potential Drugs
 • 2024  • DOI: 10.3390/ijms251910475
View Source
Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration
 • 2023  • DOI: 10.1016/j.isci.2023.107321
View Source
Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer's Disease
 • 2023  • DOI: 10.3390/antiox12081628
View Source
AgRP neurons: Regulators of feeding, energy expenditure, and behavior
 • 2022  • DOI: 10.1111/febs.16176
View Source
Systematic review of clinical evidence on postoperative delirium: literature search of original studies based on validated diagnostic scales
 • 2021  • DOI: 10.1186/s44158-021-00021-8
View Source
Neuron-Oligodendrocyte Interactions in the Structure and Integrity of Axons
 • 2021  • DOI: 10.3389/fcell.2021.653101
View Source
Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications
 • 2020  • DOI: 10.3390/cells9071687
View Source
Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
 • 2020  • DOI: 10.1124/mol.120.119388
View Source
Metabolic Effects of Oxytocin
 • 2020  • DOI: 10.1210/endrev/bnz012
View Source
The Melanocortin System behind the Dysfunctional Eating Behaviors
 • 2020  • DOI: 10.3390/nu12113502
View Source
Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms
 • 2019  • DOI: 10.3389/fneur.2019.00282
View Source
Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy
 • 2019  • DOI: 10.1111/bph.14593
View Source
Microglia in neurodegeneration
 • 2018  • DOI: 10.1038/s41593-018-0242-x
View Source
How to reprogram microglia toward beneficial functions
 • 2018  • DOI: 10.1002/glia.23484
View Source
The role of TAM family receptors and ligands in the nervous system: From development to pathobiology
 • 2018  • DOI: 10.1016/j.pharmthera.2018.03.002
View Source
Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease
 • 2018  • DOI: 10.1016/j.bcp.2018.02.012
View Source
Mitochondrial Uncoupling Proteins: Subtle Regulators of Cellular Redox Signaling
 • 2018  • DOI: 10.1089/ars.2017.7225
View Source
Nanoparticle-Based Therapeutics for Brain Injury
 • 2018  • DOI: 10.1002/adhm.201700668
View Source
Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms
 • 2018  • DOI: 10.1016/j.pneurobio.2018.01.003
View Source
Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review
 • 2018  • DOI: 10.2174/1389202919666171229145156
View Source
Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors
 • 2017  • DOI: 10.1177/0963689717714102
View Source
GRP78 at the Centre of the Stage in Cancer and Neuroprotection
 • 2017  • DOI: 10.3389/fnins.2017.00177
View Source
Bioactivity of Olive Oil Phenols in Neuroprotection
 • 2017  • DOI: 10.3390/ijms18112230
View Source
Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders
 • 2017  • DOI: 10.1016/bs.apha.2016.06.002
View Source
Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα
 • 2017  • DOI: 10.3389/fnmol.2017.00030
View Source
POMC Neurons: From Birth to Death
 • 2017  • DOI: 10.1146/annurev-physiol-022516-034110
View Source
Biased signaling at neural melanocortin receptors in regulation of energy homeostasis
 • 2017  • DOI: 10.1016/j.bbadis.2017.04.010
View Source
Molecular Pharmacology of δ-Opioid Receptors
 • 2016  • DOI: 10.1124/pr.114.008979
View Source

60 sources · Platform research library · Not generated by AI

PNF5

Want More Detailed Research?

Ask the AI anything about PNF-α (Protective Neuropeptide Fragment) - mechanisms, trial summaries, pharmacokinetics, and comparisons.

Ask AI About PNF-α (Protective Neuropeptide Fragment)
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.